Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Robust Assessment of Genomic Imbalance in Diffuse Large B-Cell Lymphoma Confirms Inferior Outcome Is Associated with Genomic Complexity and Identifies Potential Therapeutic Pathway Targets

Lizalynn Dias, PhD, Venkata Thodima, PhD, Asha Guttapalli, M.S., Geetu Mendiratta, PhD, Sergei I Syrbu, MD, Jane Houldsworth, PhD

Blood (2014) 124 (21): 2993.

https://doi.org/10.1182/blood.V124.21.2993.2993

Published: 2014

Journal Articles

Event-Free Survival at 12 Months (EFS12) from Diagnosis Is a Robust Endpoint for Disease-Related Survival in Patients with Follicular Lymphoma in the Immunochemotherapy Era

Blood (2014) 124 (21): 1664.

https://doi.org/10.1182/blood.V124.21.1664.1664

Published: 2014

Journal Articles

IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era

Blood (2013) 122 (21): 362.

https://doi.org/10.1182/blood.V122.21.362.362

Published: 2013

Journal Articles

EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (−) Counterparts: Results From University of Iowa/Mayo Clinic SPORE

Usha Perepu, MBBS, Ahmet Dogan, MD, PhD, Matthew J Maurer, MS, Cristine Allmer, BS, Carrie A. Thompson, MD, Stephen M Ansell, Sergei I Syrbu, MD, Susan L Slager, PhD, Thomas E. Witzig, MD, George J. Weiner, MD, Thomas M. Habermann, James R Cerhan, MD, PhD, Brian K Link, MD

Blood (2012) 120 (21): 1604.

https://doi.org/10.1182/blood.V120.21.1604.1604

Published: 2012

Journal Articles

Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI

Laura S. Jacobus, MS, Julianne Lunde, MA, Matthew J Maurer, MS, Ahmet Dogan, MD, PhD, Sergei I Syrbu, MD, Cristine Allmer, Anne J. Novak, Ph.D., James R Cerhan, MD, PhD, Grzegorz S. Nowakowski, MD, Susan L Slager, PhD, Thomas E. Witzig, MD, Carrie A. Thompson, MD, George J. Weiner, MD, Thomas M Habermann, MD, Stephen M. Ansell, M.D., Ph.D., Brian K Link, MD

Blood (2012) 120 (21): 1563.

https://doi.org/10.1182/blood.V120.21.1563.1563

Published: 2012

Journal Articles

Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population

Matthew J Maurer, MS, Herve Ghesquieres, MD, PhD, Thomas E. Witzig, MD, Carrie A. Thompson, MD, Ivana N. Micallef, MD, William R Macon, MD, Sergei I Syrbu, MD, Paul Kurtin, MD, Cristine Allmer, BS, Therese Gargi, Emmanuelle Nicolas-Virelizier, MD, Catherine Sebban, MD, Susan L Slager, PhD, Thomas M Habermann, MD, Brian K Link, MD, James R Cerhan, MD, PhD

Blood (2012) 120 (21): 1540.

https://doi.org/10.1182/blood.V120.21.1540.1540

Published: 2012

Journal Articles

Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource

Brian K Link, MD, Matthew J Maurer, MS, Grzegorz S. Nowakowski, MD, Stephen M Ansell, MD, PhD, William R Macon, MD, Sergei I Syrbu, MD, Susan L Slager, PhD, Carrie A. Thompson, MD, David J. Inwards, MD, Patrick B. Johnston, MD, PhD, Joseph P. Colgan, MD, Thomas E. Witzig, MD, George J Weiner, Thomas M. Habermann, James R Cerhan, MD, PhD

Blood (2012) 120 (21): 1546.

https://doi.org/10.1182/blood.V120.21.1546.1546

Published: 2012

Journal Articles

Elevated Monoclonal Free Light Chains Are a Serum Marker of ABC Type Diffuse Large B-Cell Lymphoma

Matthew J Maurer, MS, James R Cerhan, MD, PhD, Jerry A Katzmann, PhD, Ahmet Dogan, M.D., Ph.D., Mamta Gupta, Ph.D, William R Macon, MD, Sergei I Syrbu, MD, Brian K Link, MD, Ivana N. Micallef, MD, Thomas E Witzig

Blood (2011) 118 (21): 1591.

https://doi.org/10.1182/blood.V118.21.1591.1591

Published: 2011

Journal Articles

Thymidylate Synthase (TS) Expression In Diffuse Large B-Cell Lymphoma (DLBCL): Identification of a Potential Therapeutic Target

Emilian Racila, Sergei I Syrbu, MD, Michel Nasr, MD, Malik E. Juweid, MD

Blood (2010) 116 (21): 5107.

https://doi.org/10.1182/blood.V116.21.5107.5107

Published: 2010

Journal Articles

Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival

Matthew J Maurer, James Cerhan, MD, PhD, Jerry A Katzmann, PhD, Brian Link, Ivana N Micallef, MD, Joseph Colgan, MD, Thomas M. Habermann, MD, David James Inwards, MD, Svetomir Markovic, MD, PhD, Stephen M. Ansell, MD, PhD, Luis Porrata, MD, Patrick B Johnston, MD, Grzegorz S. Nowakowski, MD, Carrie A Thompson, MD, Mamta Gupta, Ph.D, Sergei I Syrbu, MD, Paul Kurtin, MD, William Macon, MD, Thomas E. Witzig, MD

Blood (2010) 116 (21): 4136.

https://doi.org/10.1182/blood.V116.21.4136.4136

Published: 2010

Journal Articles

Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma

James R Cerhan, MD, PhD, Thomas M Habermann, MD, Matthew J Maurer, MS, James E Wooldridge, MD, Stephen M Ansell, MD, PhD, Grzegorz S. Nowakowski, MD, Ivana N Micallef, MD, Carrie A Thompson, MD, Alice H Wang, BA, William R Macon, MD, Sergei I Syrbu, MD, Susan L Slager, PhD, Thomas E Witzig, MD, Brian Link

Blood (2010) 116 (21): 996.

https://doi.org/10.1182/blood.V116.21.996.996

Published: 2010

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Robust Assessment of Genomic Imbalance in Diffuse Large B-Cell Lymphoma Confirms Inferior Outcome Is Associated with Genomic Complexity and Identifies Potential Therapeutic Pathway Targets

Event-Free Survival at 12 Months (EFS12) from Diagnosis Is a Robust Endpoint for Disease-Related Survival in Patients with Follicular Lymphoma in the Immunochemotherapy Era

IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era

EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (−) Counterparts: Results From University of Iowa/Mayo Clinic SPORE

Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI

Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population

Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource

Elevated Monoclonal Free Light Chains Are a Serum Marker of ABC Type Diffuse Large B-Cell Lymphoma

Thymidylate Synthase (TS) Expression In Diffuse Large B-Cell Lymphoma (DLBCL): Identification of a Potential Therapeutic Target

Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival

Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only